Bayer

This study follows over 800 men with non-metastatic castration-resistant prostate cancer who are already taking darolutamide as part of their normal care. Researchers are tracking side effects and how well the drug controls the cancer in real-world conditions, outside of a strict…

This study tracks over 1,000 Japanese patients with renal anemia (low red blood cells due to kidney disease) who are taking molidustat tablets. Researchers are monitoring for serious side effects like blood clots, high blood pressure, and tumors, as well as checking if red blood …

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This study tests whether the Mirena IUD, a birth control device that releases hormones, can reverse a noncancerous thickening of the uterine lining better than daily hormone pills. About 207 women with nonatypical endometrial hyperplasia will be randomly assigned to get either Mi…

This study looks at children with congenital heart disease who take the blood thinner rivaroxaban after a Fontan procedure. The goal is to see how often serious or minor bleeding happens. Researchers will collect data from regular doctor visits for up to 2 years. No extra tests o…

This observational study follows about 1,600 men with metastatic hormone-sensitive prostate cancer who are taking darolutamide plus hormone therapy, with or without chemotherapy. Researchers will track how many men have undetectable PSA levels after one year, as well as overall s…

This early-stage trial tests a new antibody, BAY 3375968, designed to help the immune system fight advanced solid tumors. It works by reducing regulatory T cells that can suppress immune activity. The study will test the drug alone and combined with pembrolizumab in about 129 peo…

This phase 3 study tests whether adding darolutamide (Nubeqa) to standard hormone therapy (ADT) can delay cancer progression in men with high-risk biochemical recurrence of prostate cancer. About 985 men whose PSA levels rose after initial treatment will receive either darolutami…

This early-stage trial tests a new drug called BAY2965501, which boosts the immune system to fight cancer. It is given alone or with other drugs like pembrolizumab and chemotherapy. The study includes about 284 people with advanced solid tumors (skin, kidney, stomach, or lung can…

This study offers continued treatment with the drug darolutamide to cancer patients who were already taking it in a previous Bayer-sponsored trial and are still benefiting. About 402 participants will keep receiving the same dose and visit their doctors regularly. The main goal i…

This early-stage study tests a new drug called 225Ac-pelgi for people with advanced prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers a short-range radioactive payload directly to cancer cells, aiming to kill them while sparing healthy t…

This study tests whether a radioactive drug called radium-223 works better than standard hormone-blocking pills (ARPI) for men with prostate cancer that has spread to the bones and is no longer responding to initial hormone therapy. About 654 participants will receive either radi…

This study follows 75 Japanese babies with retinopathy of prematurity (ROP) who are being treated with Eylea, a drug injected into the eye. ROP causes abnormal blood vessel growth in the retina and can lead to blindness. The study collects real-world data on side effects and how …

This study tests a one-time gene therapy called BAY2599023 for adults with severe hemophilia A. The therapy uses a harmless virus to deliver a working copy of the factor VIII gene, so the body can produce its own clotting factor. The trial involves 11 participants and aims to fin…

This study tests a drug called riociguat in children aged 6 to 18 who have pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe and move. The goal is to see if the drug is safe and how the body processes it at differen…

This study tracks adults with hemophilia A who choose to take Jivi, a longer-lasting clotting factor that requires fewer injections. Researchers will use ultrasound to see if joint health stays the same or improves after 24 months of treatment. The goal is to learn how well Jivi …

This study monitors 453 patients with advanced thyroid cancer that cannot be removed by surgery and does not respond to radioactive iodine. All patients are taking the drug sorafenib (Nexavar) as part of their normal care. Researchers are tracking side effects and how long patien…

This phase 3 trial is testing a drug called aficamten in 36 Japanese adults with symptomatic obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and makes it hard to pump blood. The drug aims to reduce over-contraction of the heart muscle. Researc…

This study tests whether adding darolutamide to standard hormone therapy (ADT) can delay cancer worsening in men with metastatic hormone-sensitive prostate cancer. About 223 men will receive darolutamide plus ADT, and their results will be compared to men from an earlier study wh…

This study tests a drug called elinzanetant to see if it can reduce hot flashes in women with hormone-receptor positive breast cancer who are on hormone-blocking therapy. About 474 women will take either the drug or a placebo for 12 weeks, then all will receive the drug for up to…

This study reviews medical records of 1200 Indian adults with chronic kidney disease and type 2 diabetes who started finerenone between August 2022 and April 2024. Researchers will analyze how doctors prescribed the drug, dose changes, and lab results like kidney function and pot…

This study examines medical records from 10,000 people who had sepsis (blood poisoning) and developed dangerous blood clots (VTE) while in the ICU. Researchers want to see how many also had a serious blood disorder called DIC, which can cause clots throughout the body. By looking…

This observational study follows 300 adults with advanced liver cancer that cannot be removed by surgery. All participants have already received a first-line immunotherapy combination (like atezolizumab plus bevacizumab). Researchers will collect data from routine care to see how…

This study collects information from medical records of 700 Canadian men with metastatic hormone-sensitive prostate cancer (mHSPC). Researchers want to see how doctors actually combine treatments like hormone therapy, newer drugs, or chemotherapy in everyday practice. No new trea…

This study looks at how many women with multiple sclerosis (MS) use the drug interferon-beta during the second and third trimesters of pregnancy in Finland and Sweden. Researchers want to know if there are enough cases to study whether the drug affects pregnancy outcomes like bir…

This study looks at how the drug Jivi (damoctocog alfa pegol) works for people with hemophilia A in real-world settings, not just in controlled trials. Researchers are tracking bleeding episodes, side effects, and how satisfied patients and doctors are with the treatment. About 3…

This observational study follows 150,000 people with chronic kidney disease and type 2 diabetes to see how finerenone (Kerendia) works in everyday medical care. Researchers will compare those taking finerenone to those not taking it, looking at rates of heart attacks and heart fa…

This study follows 62 people with hemophilia A who are already using Jivi (a long-acting clotting factor) to prevent bleeding. Researchers will track safety events like side effects and lab changes over at least 4 years during routine doctor visits. The goal is to better understa…

This observational study will follow 2,500 adults with vision loss from nAMD or DME who are already prescribed aflibercept 8 mg by their doctors. Researchers will collect data from routine visits over up to 24 months to see how vision changes. The goal is to understand how well t…

This observational study follows over 4,600 adults with chronic kidney disease and type 2 diabetes who are starting finerenone, a drug that helps slow kidney damage. Researchers will collect data from routine doctor visits over 12 months to understand why doctors prescribe it, ho…

This observational study is collecting data from Japanese men with metastatic hormone-sensitive prostate cancer who are already receiving darolutamide plus standard hormone therapy and chemotherapy. The main goal is to track heart-related side effects and other safety issues in r…

This study looks at medical records from over 600 Indian adults with chronic heart failure who were prescribed vericiguat between 2022 and 2023. Researchers want to see how the drug is used in routine care, how well it works, and what side effects occur. No new tests or visits ar…

This observational study examines how aflibercept 8 mg, an injection into the eye, is used in routine care for patients in Japan with age-related macular degeneration or diabetic macular edema. Researchers will analyze claims data from about 3000 patients to understand patient ch…

This study was designed to see how a new experimental drug for chronic kidney disease, nurandociguat, affects the way the body processes two common medicines: rosuvastatin (a cholesterol drug) and dabigatran (a blood thinner). Healthy adults would have taken these drugs alone and…